Real-time enrollment status for this metastatic castration-resistant prostate cancer clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 5:31 PM UTC
| NCT Number | NCT07611110 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Castration-resistant Prostate Cancer |
| Phase | PHASE3 |
| Target Enrollment | 670 participants |
| Active Locations | 26 sites in the US |
| Sponsor | AstraZeneca |
| Last Updated on CT.gov | August 26, 2026 (Aug 26, 2026) |
As of October 12, 2026: Clinical trial NCT07611110 is currently recruiting participants. This phase3 study for metastatic castration-resistant prostate cancer is actively seeking new participants at 26 locations across the United States. The study is sponsored by AstraZeneca. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07611110 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 26 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07611110 was last updated Aug 26, 2026 (August 26, 2026). HelloStudys verifies this status automatically.